Johnson & Johnson JNJ IMBRUVICA — Percent Change (as a percent)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept jnj:PercentageChangeInSalesBySegmentOfBusiness.
The official record: Johnson & Johnson’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Johnson & Johnson's imbruvica — percent change (as a percent).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Johnson & Johnson's IMBRUVICA — percent change (as a percent)?
- Johnson & Johnson (JNJ) reported IMBRUVICA — percent change (as a percent) of -18.6% in Q2 2026.
- How has Johnson & Johnson's IMBRUVICA — percent change (as a percent) changed year-over-year?
- Johnson & Johnson's IMBRUVICA — percent change (as a percent) decreased by 313.3% year-over-year, from -4.5% to -18.6%.
- What does IMBRUVICA — percent change (as a percent) mean?
- This metric measures the period-over-period percentage growth or decline in net sales for a specific pharmaceutical product. It provides a normalized view of the product's momentum, stripping away absolute scale to highlight the underlying trajectory of market penetration or saturation. This is essential for evaluating whether a product is in a growth, maturity, or decline phase of its commercial lifecycle.